Alendronate (Fosamax): Mechanism, Dosing, and How to Take It Correctly

Does Alendronate Come as an Injection?

Alendronate does not come in an injectable form. Every FDA-approved formulation is oral: a 10 mg daily tablet, a 35 mg once-weekly tablet, a 70 mg once-weekly tablet, and a 70 mg oral solution [1]. Patients searching for a "Fosamax self-injection technique" are likely confusing alendronate with zoledronic acid (Reclast), which is given as a 5 mg intravenous infusion once yearly, or with denosumab (Prolia), a subcutaneous injection given every six months.

If your prescriber has discussed injectable osteoporosis therapy, confirm the exact drug name before proceeding. Administering the wrong agent is a medication-safety event. The section below covers injectable osteoporosis alternatives in brief, and the rest of this article focuses on alendronate's mechanism, evidence base, and correct oral administration.

Injectable Alternatives to Alendronate

Zoledronic acid 5 mg IV (Reclast) reduces hip fracture risk by 41% over three years in the HORIZON Key Fracture Trial (N=7,765) [2]. Denosumab 60 mg subcutaneous every six months reduced vertebral fracture risk by 68% over 36 months in the FREEDOM trial (N=7,808) [3]. Teriparatide (Forteo) and abaloparatide (Tymlos) are daily subcutaneous injections reserved for high-fracture-risk patients.

If you need technique guidance for denosumab or teriparatide self-injection, those are separate clinical topics. For alendronate, the administration skill that matters is oral technique, not injection technique.

How Alendronate Works: The Mechanism in Detail

Alendronate suppresses bone resorption by accumulating in hydroxyapatite at active remodeling sites and poisoning the mevalonate pathway inside osteoclasts [4]. The result is less bone turnover, a net increase in bone mineral density (BMD), and lower fracture rates.

Binding to Bone Mineral

After oral absorption (roughly 0.6-0.7% bioavailability in the fasted state), alendronate is taken up rapidly by bone surfaces that are actively resorbing [5]. Because it has a very high affinity for calcium phosphate crystals, roughly 50% of the absorbed dose deposits in bone within hours; the rest exits in urine unchanged [4].

The drug stays embedded in bone matrix for years. This explains why a "drug holiday" after five years of treatment is clinically reasonable: residual skeletal drug continues to suppress resorption for months to years after the last dose [6].

Blocking the Mevalonate Pathway

Once an osteoclast begins resorbing bone, it ingests alendronate along with the mineral. Inside the cell, alendronate inhibits farnesyl pyrophosphate synthase, an enzyme in the mevalonate cholesterol-synthesis pathway [4]. Without this enzyme, osteoclasts cannot prenylate signaling proteins (Ras, Rho, Rac), which are needed for cytoskeletal integrity and cell survival. The osteoclast undergoes apoptosis. Bone resorption stalls.

This mechanism is distinct from that of denosumab, which blocks RANK-L, the cytokine that recruits and activates osteoclasts in the first place [3].

Effect on Bone Remodeling Balance

Bone constantly cycles through resorption and formation. Alendronate does not stimulate osteoblast activity directly; it simply reduces the resorption half of the cycle. Over months, this shifts the balance toward net mineral accumulation, raising BMD on DXA scanning. Lumbar spine BMD typically increases 5-8% over three years; hip BMD rises 2-3% [7].

The Evidence: Fracture Reduction Trials

FIT: The Landmark Vertebral Fracture Trial

The Fracture Intervention Trial (FIT, JAMA 1998, N=2,027) enrolled postmenopausal women with existing vertebral fractures and femoral neck T-scores at or below -1.6 [7]. Over three years, alendronate 5-10 mg daily produced:

• 47% relative risk reduction in new vertebral fractures (8.0% vs. 15.0%, P<0.001) [7]
• 51% relative risk reduction in hip fractures (1.1% vs. 2.2%, P=0.047) [7]
• 56% relative risk reduction in wrist fractures [7]

The trial authors wrote: "Alendronate treatment reduced the risk of new vertebral fractures and clinical fractures by approximately one half" [7]. This remains the most-cited efficacy datum for alendronate.

FIT Arm 2: Women Without Existing Fractures

A second FIT arm (N=4,432) enrolled women with low BMD but no prior vertebral fracture. Over four years, alendronate reduced clinical fractures by 36% in the subgroup with femoral neck T-score at or below -2.5 [8]. Women with T-scores between -2.5 and -1.6 showed smaller, non-significant reductions in that subgroup, emphasizing that absolute fracture risk at baseline drives the benefit-to-risk calculation [8].

FLEX: How Long Should Treatment Continue?

The Fracture Intervention Trial Long-Term Extension (FLEX, JAMA 2006, N=1,099) followed women who had taken alendronate for five years and then randomized them to continue or switch to placebo for another five years [6]. Continuing alendronate for ten years produced no significant reduction in non-vertebral fractures compared to stopping at five years, but did reduce clinical vertebral fractures by 45% in a subgroup with femoral neck T-score below -2.5 at the five-year mark [6].

The FLEX data underpin current American College of Rheumatology and National Osteoporosis Foundation guidance: reassess after three to five years of oral bisphosphonate therapy and consider a drug holiday for low-to-moderate risk patients [9].

The HealthRX clinical team uses a three-tier reassessment framework at the five-year mark: (1) patients with femoral neck T-score above -2.5 and no incident fractures may take a two-to-three year holiday; (2) patients with T-score below -2.5 or a hip fracture while on therapy should continue or switch to an anabolic agent; (3) patients with very high risk (two or more fragility fractures, T-score below -3.0) should transition to teriparatide or abaloparatide before resuming alendronate.

FDA-Approved Indications and Dosing

The FDA label covers five indications with distinct doses [1]:

| Indication | Dose | Frequency | |---|---|---| | Treatment of postmenopausal osteoporosis | 70 mg | Once weekly | | Prevention of postmenopausal osteoporosis | 35 mg | Once weekly | | Treatment of osteoporosis in men | 70 mg | Once weekly | | Glucocorticoid-induced osteoporosis | 5 mg daily or 35 mg weekly | Daily or weekly | | Paget's disease of bone | 40 mg | Daily for 6 months |

The 70 mg once-weekly tablet has equivalent efficacy to 10 mg daily in head-to-head trials, with comparable gastrointestinal tolerability [10]. Once-weekly dosing exists entirely for adherence convenience, not for a pharmacokinetic advantage.

Correct Oral Administration Technique

Getting the administration right is not optional. Alendronate causes clinically significant esophagitis and esophageal ulceration if it remains in contact with mucosal tissue [1]. A case series published in the New England Journal of Medicine documented severe esophageal injury in patients who took alendronate with too little water, lay down after dosing, or took it at bedtime [11].

Step-by-Step Administration Protocol

Follow these steps every time:

1. Take alendronate first thing in the morning, before any food, drink, or other medications.
2. Swallow the tablet with a full 240 mL (8 oz) glass of plain water. Mineral water, coffee, juice, and calcium-enriched drinks all reduce absorption and may increase local irritation [1].
3. Remain upright, either standing or sitting fully erect, for at least 30 minutes after swallowing [1].
4. Do not eat, drink anything other than plain water, or take other oral medications for at least 30 minutes. Calcium supplements and antacids should be taken at a different time of day.
5. If you miss a weekly dose, take it the next morning. Do not take two doses on the same day.

Why Upright Posture Matters

Gravity keeps the tablet and any residual drug moving toward the stomach. If a patient reclines, the tablet may lodge in the lower esophagus and release drug against the mucosa. The resulting chemical esophagitis can mimic cardiac chest pain and, in severe cases, requires endoscopy [11].

Swallowing Difficulty: When to Switch Agents

Patients with known esophageal stricture, achalasia, Barrett's esophagus, or any condition that delays esophageal emptying should not take oral alendronate [1]. Zoledronic acid IV or denosumab SC are appropriate alternatives. The prescriber, not the patient, should make that switch.

Who Should Not Take Alendronate

Several contraindications appear on the FDA label and in ACC/AHA and endocrine society guidance [1, 9]:

• Abnormalities of the esophagus that delay emptying (stricture, achalasia)
• Inability to stand or sit upright for at least 30 minutes
• Hypocalcemia (correct before starting)
• eGFR <35 mL/min per 1.73 m² (the drug accumulates and efficacy data are lacking)
• Hypersensitivity to any component

Patients with vitamin D deficiency should have it corrected before starting, because alendronate can worsen hypocalcemia in D-deficient individuals [1].

Monitoring: What Labs and Scans to Expect

Bone Mineral Density by DXA

Baseline DXA of lumbar spine and hip is standard before starting treatment. A follow-up scan at 1-2 years confirms the patient is a responder. The International Society for Clinical Densitometry defines a "least significant change" of roughly 3-5% at the lumbar spine [12]. A loss of BMD on therapy despite good adherence warrants a secondary cause workup and possible agent change.

Bone Turnover Markers

Serum C-terminal telopeptide (CTX) and urine N-telopeptide fall within three to six months of starting alendronate. A 50-70% reduction from baseline CTX is the expected response [9]. Persistently elevated markers suggest malabsorption, poor adherence, or secondary hyperparathyroidism.

Calcium and Vitamin D

Serum calcium, 25-OH vitamin D, and comprehensive metabolic panel should be checked at baseline. Ongoing supplementation of calcium 1,000-1,200 mg/day and vitamin D 600-800 IU/day (higher in deficient patients) is recommended alongside alendronate [9].

Adverse Effects: What the Evidence Shows

Gastrointestinal Events

Upper GI events are the most common reason patients stop alendronate. The FACT trial (N=1,053) found that 70 mg once-weekly alendronate produced significantly fewer upper GI adverse events than 10 mg daily dosing (p=0.023) [10]. Heartburn, nausea, and abdominal pain affect roughly 10-15% of users; frank esophageal ulceration is less common but serious [1].

Osteonecrosis of the Jaw

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) occurs at a rate of roughly 1 in 10,000 to 1 in 100,000 patient-treatment years with oral bisphosphonates at osteoporosis doses [13]. Risk is far higher with IV bisphosphonates used in oncology. Dental procedures should be completed before starting alendronate when possible; inform your dentist of the medication.

Atypical Femoral Fractures

Atypical subtrochanteric femoral fractures are rare but have been associated with long-term bisphosphonate use. The absolute risk remains very low: the American Society for Bone and Mineral Research (ASBMR) task force estimated a risk of 3.2-50 per 100,000 person-years depending on duration of use [14]. Thigh or groin pain without trauma warrants imaging.

Musculoskeletal Pain

The FDA added a warning in 2008 about severe, occasionally incapacitating bone, joint, and muscle pain [1]. Onset may occur days to months after starting. The pain typically resolves after stopping the drug.

Drug Interactions

Calcium supplements, antacids, and other oral medications taken within 30 minutes of alendronate will chelate the drug and reduce already-low absorption [1]. Nonsteroidal anti-inflammatory drugs (NSAIDs) taken concurrently may increase upper GI irritation. No clinically significant cytochrome P450 interactions have been identified, because alendronate is not hepatically metabolized [4].

Special Populations

Men With Osteoporosis

FIT enrolled only women. The evidence in men comes from a two-year randomized trial (N=241, NEJM 2000) showing alendronate 10 mg daily increased lumbar spine BMD by 7.1% vs. 1.8% placebo, with a significant reduction in vertebral fractures [15]. The 70 mg once-weekly dose is FDA-approved for men based on pharmacokinetic bridging data [1].

Glucocorticoid-Induced Osteoporosis

Long-term glucocorticoid use (prednisone 5 mg/day or more for three or more months) is the leading cause of secondary osteoporosis. Alendronate 5 mg daily or 35 mg weekly is approved for this indication. The ACR 2022 guideline recommends oral bisphosphonates as first-line therapy for most patients on long-term glucocorticoids, provided no contraindications exist [9].

Premenopausal Women

Alendronate is generally not used in premenopausal women except in glucocorticoid-induced osteoporosis, given the lack of fracture-endpoint data and teratogenicity concerns. The drug has a very long skeletal half-life and could theoretically affect fetal bone development if pregnancy occurs during or after a treatment course [1].